Dew, yes I saw the drop in IMGN. The previous response rate using mirvetuximab was for 20 patients and at 35% represented 7 patients. From a simple calculation, with 46 patients an RR just under 30% is 13 patients (13/46 = 28.2%). Obviously it would have been better to go up but I don't think the difference is that concerning as one hardly expects 20 patients to hit the real world RR in a larger trial.
Two other posters accurately expressed the pros (skitahoe) and cons (xavierprivas) of IMGN regarding the accurately so I won't rehash them. My view is that the move is risky because IMGN is going for a bigger score at the expense of time and money. If IMGN had stuck to their previous approach, they would have had time to get a partner if the results were encouraging. Now they are rolling the dice. I need to see the breakdown of high and medium folate receptor expressing patients in the updated at ASCO.
I fully understand the drop in IMGN stock price, but decided to buy some yesterday anyway. I don't have a lot of IMGN shares even after the buy was able to increase my shares by 40% at $6.81. So why did I end adding to my small number of shares? Well, the simplistic answer is that risk is higher so the price is lower. A longer view is that I think ADCs have been given a shrift due to the rise of Immune modulators. I own more SGEN than IMGN and saw then ABBV bought another ADC company, and since I own that too I have covered the bases.
The thing from the CC that caught my eye was regarding Forward II, where IMGN is testing mirvetuximab as a combination therapy. One of those combination they are going to add is Keytruda. It seemed counterproductive to me to combine a checkpoint inhibitor with drugs that inhibit or damage proliferating cells, like say docetaxel with Abs designed to promote T cell proliferation. What you would want to combine checkpoint inhibitors with things that preferentially target tumors cells, such as ADCs or hormonal inhibitors like tamoxifen or anti-androgens. I know I am jumping the gun by a lot in this regard with IMGN. If I were smart I would wait until the first data comes in from the FORWARD II arm of mirvetuximab + Keytruda, or at least began dosing, but nobody ever accused me of being smart with my money. In my defense, I may have been feeling a bit giddy due to MDVN rising. In any event that is something worth watching for in the future in my view and jumping on if the data looks promising.
AI
